Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hansoh Seeks to Raise $1 Billion at Top of Hong Kong IPO Range

publication date: May 31, 2019

Hansoh Pharma, a generic/novel drug company headquartered in Lianyungang, Jiangsu province, has set the pricing range in an upcoming Hong Kong IPO slated to raise up to $1 billion at a $10 billion valuation. Hansoh has signed up nine cornerstone investors who will purchase $344 million of the IPO. A profitable company, Hansoh reported $1.1 billion in 2018 revenues and more than $280 million in profits, a 19% increase from the year earlier. At a $10 billion market cap, Hansoh would be priced at 36 times trailing earnings. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here